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Background: Endothelial nitric oxide synthase type III is the key enzyme of the
nitric oxide production in the vessel wall. In this study the localization of endothelial
nitric oxide synthase type III within the wall of the human internal thoracic and
radial arteries and the great saphenous vein was investigated.
Methods: Specimens were harvested from 23 patients undergoing surgical myocar-
dial revascularization and submitted to light and electron microscope analysis using
histochemical stainings and immunohistochemistry with specific antibodies anti-
endothelial nitric oxide synthase type III, Factor VIII, and -smooth muscle actin.
Results: Endothelial nitric oxide synthase type III was evident in the intima of all
conduits and, unexpectedly, in the muscle cells of the media of muscular internal
thoracic arteries and radial arteries. No endothelial nitric oxide synthase type III
expression was found in the media of great saphenous veins. Semiquantitative
analysis revealed a higher endothelial nitric oxide synthase type III expression in the
wall of internal thoracic artery, particularly at the level of the media.
Conclusion: Endothelial nitric oxide synthase type III is expressed in the intima of
the internal thoracic and radial artery and the great saphenous vein and in the muscle
cells of the media of the internal thoracic and radial arteries. However, the internal
thoracic artery shows a higher intensity of endothelial nitric oxide synthase type III
expression, particularly within the media. The present study provides the first
demonstration of the endothelial nitric oxide synthase type III expression at the level
of the smooth muscle cells of the tunica media of systemic human arteries and can
provide an histologic explanation for the better results of the internal thoracic artery
when used for coronary artery bypass grafting.
Nitric oxide (NO) is involved in several intracellular and intercel-lular signaling functions, such as regulation of blood vessel tone,hearth rhythm, cellular respiratory activity, response to inflam-mation, growth-promoting effects, neuronal signal transmission,vasodilatation, and resistance to atherosclerosis.1,2 EndogenousNO is produced by the enzyme nitric oxide synthase (NOS) from
the conversion of L-arginine to L-citrulline.3 In mammals, three isoforms of NOS
have been identified. NOS I (b-NOS, n-NOS)4 and NOS III (e-NOS)5, regulated by
Ca2, are constitutively expressed respectively in neurons and in endothelial cells;
in contrast NOS II (i-NOS)6 is an inducible form, Ca2 independent, whose
expression is induced by cytokines or other inflammatory agents. The three isoforms
displayed regions of high homology but, at the same time, each one is characterized
by structural differences that reflect its specific function.7
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Although it is usually thought that NOS III is expressed
only by the endothelial layer,8,9 the localization of this
enzyme in the wall of the conduits used for surgical myo-
cardial revascularization has not been investigated in detail.
In the present study we used specific antibodies to localize
NOS III within the human internal thoracic artery (ITA),
radial artery (RA), and great saphenous vein (GSV).
Methods
After obtaining informed consent for specimen collection, samples
of left ITA, RA, and GSV were collected from 23 patients during
coronary artery bypass procedures. Main preoperative data of these
patients are summarized in Table 1. At the time of operation no
patient was taking medications known to influence NOS III ex-
pression.
The ITA, RA, and were harvested pedicled using a technique
described in details elsewhere,10,11 whereas the GSV was har-
vested using the conventional method.
The specimens for the microscope studies were obtained from
the distal portion of the conduits immediately after harvesting and
before surgical dilatation; the remaining part of the vessels was
used for myocardial revascularization.
For light microscope study, tissue samples were immediately
fixed in Bouin’s solution at room temperature (RT) for 24 hours.
They were then rinsed in phosphate-buffered saline (PBS; pH 7.4),
dehydrated in an ascending series of alcohol and embedded in
paraffin via xylene. Serial transverse sections of 5 m were then
cut and processed for histochemical (Mallory’s trichrome method
modified according to Azan, hematoxylin and eosin, Unna-Tanzer-
Livini stain for elastic fibers) or immunohistochemical studies. For
immunohistochemical experiments, endogenous peroxidase activ-
ity was quenched with 0.5% H2O2 in absolute methanol for 30
minutes at RT; slides were then permeabilized with 0.2% Triton
X-100 in PBS (20 min at RT) and incubated with 3% normal goat
serum in PBS (30 min at RT) to block nonspecific binding.
Sections were then incubated overnight at 4°C with the following
primary antibodies: rabbit polyclonal anti-human NOS III (Santa
Cruz Biotechnology, Santa Cruz, Calif, final concentration 2 g/
mL), rabbit polyclonal anti-human NOS III (Transduction Lab.,
Ky, final concentration 5 g/mL), rabbit polyclonal anti-human
Factor VIII (YLEM, Milan, Italy, diluted 1:150), mouse monoclo-
nal anti-human -smooth muscle actin (-SMA) (Novocastra Lab-
oratories, Peterborough, UK, diluted 1:50). -SMA immunostain-
ing was utilized to identify smooth muscle cells on the basis of the
reported expression of this antigen by the smooth muscle cells.12
For double-staining experiments, antibodies to NOS III and to
-SMA were incubated on the same section simultaneously.
Control sections were treated either with normal rabbit immu-
noglobulins or with NOS III antibody at the described concentra-
tion preabsorbed (ratio, 1:5) with the peptide against which the
antibody was raised (Santa Cruz Biotechnology) at the same
concentration used for primary antibodies.
Reactions were revealed by standard avidin-biotin peroxidase
complex procedure (Vectastain Elite ABC Kit; Vector, Burlin-
game, Calif) using 3,3' diaminobenzidine tetrahydrochloride
(DAB) (Sigma, Milan, Italy) and 3'-amino-9-ethylcarbazole (AEC
Substrate Kit; Vector) as cromogens for anti-Factor VIII and
anti--SMA labeling, respectively. The anti-NOS III reaction was
demonstrated by standard avidin-biotin alkaline phosphatase com-
plex procedure (Vectastain Elite ABC-AP Kit; Vector) using
BCIP-NBT (Sigma, Italy) as substrate.
Sections were examined under a Zeiss Axiophot (Aalen, Ger-
many) light microscope.
For electron microscope observation, tissue samples were fixed
in 4% paraformaldehyde in PBS for 4 hours at 4°C, dehydrated in a
graded ethanol series, and embedded in LR-White (London Resin
Company, London, UK). Ultrathin sections were prepared using a
Reichert ultramicrotome (Leica, Solms, Germany), collected on
Formvar carbon-coated nickel grids, and then incubated overnight
at 4°C with the polyclonal antibody to human NOS III (Santa Cruz
Biotechnology, final concentration 2 g/mL). After repeated
washing in PBS, ultrathin sections were incubated with goat anti-
rabbit IgG gold (5 nm) conjugated (Sigma, Chemicals) diluted
1:50 in PBS containing 1% bovine serum albumin for 2 hours at
RT. Negative controls were done by omitting the anti-human NOS
III antibody, or adding the NOS III antibody at the described
concentration preadsorbed with the peptide against which the
antibody was raised (Santa Cruz Biotechnology) at the same
concentration used for primary antibody. Sections were then post-
fixed in 2.5% glutaraldehyde for 10 minutes, lightly counterstained
with lead citrate and observed with a Philips EM 400 microscope.
Microscopic analysis was performed by two experienced ob-
servers, blinded to each other, on a minimum of 30 sections for
light microscopy and 15 for electron microscopy from different
parts of each specimen. NOS III immunoreaction was then graded
according to a 4-degree () semiquantitative scale; discor-
dance was resolved after conjunct reevaluation.
Results
Light Microscope Study
All transverse sections from each specimen stained by his-
tochemical techniques exhibited similar tissue architecture,
and no pathological changes were noted.
Histochemical staining and anti -SMA immunoreaction
revealed that 7 ITA specimens showed a muscular tunica
TABLE 1. Preoperative characteristics of the patients
ITA RA GSV
Male/female 8/4 7/3* 6/4*
Mean age (y) 63.8 6.9 69.1 6.7 65.2 4.8
Hypertension 7 6 5
Diabetes 3 2 2
Smoking 9 6 5
Dislipemia 6 4 5
Familiar history of CAD 6 5 5
Previous AMI 4 3 5
CCS I 2 1 0
CCS II 4 5 5
CCS III 6 4 5
AMI, Acute myocardial infarction; CAD, coronary artery disease; CCS,
Canadian Cardiovascular Society; GSV, great saphenous vein; ITA, internal
thoracic artery; RA, radial artery.
*In 9 patients, both the radial artery and the saphenous vein were har-
vested.
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media, while the remaining 5 ITAs had an elastic wall. All
examined RAs revealed a muscular tunica media, whereas
GSV specimen contained only sparse smooth muscle cells
in the media.
The immunohistochemical study using the antibody to
Factor VIII showed a strong reaction in the cytoplasm of the
endothelial cells, revealing the presence of an intact endo-
thelial layer in all ITA, RA, and GSV specimens. In all
cases, NOS III immunolocalization was observed in the
cytoplasm of the endothelial cells of all types of conduits;
not all of the endothelial cells expressed NOS III immuno-
reactivity and the reaction appeared weaker than that ob-
Figure 1. NOS III and -SMA immunohistochemistry on transverse sections from the muscular part of an internal
thoracic artery specimen. A, NOS III immunoreactivity in endothelial cells and in smooth muscle cells of the tunica
media (80). B, -SMA immunoreactivity in smooth muscle cells of the tunica media (500). C, NOS III
immunoreactivity in smooth muscle cells of the tunica media and in some endothelial cells at higher magnification
(500). D, Double immunostaining with anti -SMA (red) and anti NOS III (blue) antibodies, most of smooth muscle
cells express both immunoreactions (500).
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served using the anti-Factor VIII antibody. Both anti-NOS
III antibodies exhibited the same distribution pattern.
Unexpectedly, NOS III immunoreactivity was also ob-
served within the smooth muscle cells of the tunica media
from those ITAs with a muscular wall and from RA spec-
imens (Figures 1 and 2). The intensity of NOS III immu-
noreactivity in the muscle cells varied widely from patient
to patient, but the NOS III expression in muscle cells was
present in all sections obtained from muscular ITAs and
RAs. The localization in smooth muscle cells was con-
firmed by double immunostaining experiments where anti-
NOS III and anti–-SMA antibodies were simultaneously
incubated on the same section; in these cases most of cells
labeled by -SMA antibody also expressed NOS III immu-
noreactivity in the cytoplasm (Figure 1). No NOS III ex-
pression in the tunica media was found in sections from
elastic-walled ITA and GSV specimens (Figure 3).
No immunoreactivity was detected in control sections
incubated with either normal rabbit immunoglobulins or
NOS III antibody preabsorbed with the peptide.
A semiquantitative evaluation of NOS III expression in
the different conduits is provided in Table 2.
Figure 2. NOS III immunohistochemistry on transverse sections from a radial artery specimen. NOS III immuno-
reactivity in endothelial cells and in smooth muscle cells of the tunica media (200).
Figure 3. NOS III immunohistochemistry on transverse sections from a great saphenous vein specimen. NOS III
immunoreactivity limited to endothelial cells (200).
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Electron Microscope Study
Transmission electron microscope study showed a NOS III
distribution pattern similar to that observed by light micro-
scope. NOS III localization was found in the endothelial
cells of all conduits and in the smooth muscle cells of the
arterial tunica media in all muscular ITAs and all RAs
examined (Figure 4). No NOS III expression was observed
in the tunica media of the ITAs with elastic media, in GSVs,
and in the control sections.
Discussion
In the human cardiovascular system, NO is known to play a
central role in several central functions, such as vasodilata-
tion and resistance to atherosclerosis.1-3
Endogenous NO is produced by the three isoforms of the
enzyme NOS from the conversion of L-arginine to L-citrul-
line.3-5
Although it is usually accepted that in the vessel wall
NOS III is expressed only by the endothelial layer,8 the
distribution of this isoform in human systemic arteries has
not been directly investigated to date and no description of
NOS III expression within the wall of conduits used for
surgical myocardial revascularization has been published.
Our light and electronic microscope observations con-
firm the endothelial localization of NOS III in all types of
conduits examined, although the ITA showed a higher de-
gree of endothelial expression of the enzyme. More surpris-
ingly, our data provide the first description of an additional
NOS III expression in the vascular smooth muscle cells of
the media of both the ITA and (to a lesser extent) the RA,
but not the GSV. The NOS III localization in smooth muscle
cells was confirmed by double immunostaining experi-
ments, where NOS III and -SMA antibodies were incu-
bated on the same section. We found in fact that most of
vascular muscle cells expressing -SMA immunoreactivity
were also positive for NOS III (see Figure 1).
Medial expression of NOS III in systemic human arteries
had not been described before, however, this finding is
consistent with the localization of the enzyme in different
types of muscle cells (cardiac myocites, myometrial smooth
muscle cells, and erector pili muscle).13-15
Semiquantitative analysis revealed that, although NOS
III was present in the intima of all conduits and in the media
of muscular ITAs and all RAs, the intensity of the immu-
noreactivity was different in the three examined conduits
and the ITA showed a higher NOS III expression in both the
intima and, most of all, the media.
It is widely accepted that the ITA has peculiar biological
features that render this artery an almost ideal conduit for
surgical myocardial revascularization. Biological, morpho-
logical, and angiographic studies have, in fact, clearly dem-
onstrated how this artery is somewhat protected from the
development of atherosclerosis even in patients with severe
coronary artery disease, and has better angiographic results
than all other conduits used for coronary artery bypass
grafting.16-18 NO is known to play an important protective
role against the development of atherosclerosis and, espe-
cially, graft disease.19,20 In fact, experimental investigations
have clearly shown how the basal and stimulated release of
NO are significantly greater in the ITA than in the RA and
GSV, and it has been proposed that the higher NO produc-
tion may be one possible explanation for the intrinsic pro-
tection from atherosclerotic disease and better patency rates
of ITA grafts.21,22 Our results seem to suggest that higher
NOS III expression (especially at the level of the media)
may be one explanation for the peculiar biological proper-
ties of this conduit (although no information on the func-
tional role of medial NOS III can be drawn from this
immunohistochemical analysis).
In conclusion, NOS III is found in the intima of the ITA,
RA, and GSV. Furthermore, the enzyme is also expressed in
TABLE 2. Semiquantitative evaluation of NOS III expres-
sion in the different conduits
ITA RA GSV
Intima   
Media  / —
GSV, Great saphenous vein; ITA, internal thoracic artery; RA, radial artery.
Figure 4. Electron microscope immunohistochemistry with anti-
NOS III antibody on transverse sections from the muscular part of
an internal thoracic artery specimen. The immunoreactivity is
localized in endothelial cells and in smooth muscle cells of the
tunica media (original magnification: 25,000).
Cardiopulmonary Support and Physiology Gaudino et al
1514 The Journal of Thoracic and Cardiovascular Surgery ● June 2003
CPS
the muscle cells of the media of the ITA and the RA (but not
the GSV), although the ITA shows a considerably higher
intensity of medial localization. These findings provide one
possible structural explanation for the peculiar biological
properties of the human ITA and, coupled with the higher
production of NO in the ITA compared to the RA and GSV
as described,21,22 may explain the better patency rates of
ITA grafts.
Further investigation should focus on the extent of mus-
cular NOS III contribution to the total vascular NO produc-
tion in different conditions and the factors that eventually
modulate this action.
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